Ardelyx, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 5th, 2019 • Ardelyx, Inc. • Pharmaceutical preparations • New York
Introductory. Ardelyx, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 20,000,000 shares of its common stock, par value $0.0001 per share (the “Shares”). The 20,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 3,000,000 Shares as provided in Section 2. The additional 3,000,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Citigroup Global Markets Inc. (“Citigroup”), Cowen and Company, LLC (“Cowen”), SVB Leerink LLC (“SVB Leerink”) and Piper Jaffray & Co. (“Piper”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”)
